Navigation Links
Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer

AMESBURY, Mass., Aug. 23 /PRNewswire/ -- Fluidnet Corporation (, an innovator of advanced intravenous (IV) infusion systems, announced today that its Board of Directors has unanimously appointed Benjamin E. Bulkley as President and Chief Executive Officer, effective immediately. He succeeds the company's Founder, Jeffrey Carlisle, who will serve as Fluidnet's Chief Innovation Officer.

On behalf of the Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is fortunate to have Ben to lead the company through FDA clearance of its innovative infusion delivery system and drive the growth of the business. His operating successes in the healthcare IT, life sciences, medical device, and transportation industries represent a perfect mix for Fluidnet. His track record growing global businesses and delivering highly reliable, interconnected systems will pay great dividends for the doctors, nurses, and patients that rely on these systems every day."

According to the FDA, more than 56,000 adverse events and over 700 patient deaths over the past five years have been attributed to faulty infusion system design. The Fluidnet system, once cleared, will offer a transformational change in performance. Based on a decade of user-driven innovation, its architecture is the marriage of advanced fluidics, consumer electronics, and state-of-the-art software development methods.

"The opportunity to substantially improve the safety, usability, and reliability of infusion therapy is striking," said Mr. Bulkley. "Providers and regulators are clearly demanding an easier-to-use and more trustworthy solution. I am very excited to be joining such a strong team dedicated to this mission."

Fluidnet closed a Series B financing round of $9.1 million in March of this year to fund ongoing product development, regulatory, and market preparation efforts. The worldwide market for advanced IV delivery systems and accessories is estimated at $3 billion.

Mr. Bulkley was most recently the Chief Operating Officer of Allscripts, a leader in software, services, and connectivity solutions for healthcare providers. He previously led the global commercial operations of Invitrogen, an innovator of biological tools for life science research. He joined Invitrogen after 16 years with the General Electric Company in a variety of leadership roles in the healthcare, energy and transportation fields, ultimately leading the global service business for GE's healthcare IT division.  Mr. Bulkley began his career in systems engineering and program management roles innovating high reliability, low cost solutions in the transportation industry.

Mr. Bulkley holds a Bachelor of Science degree in Electrical Engineering from the University of Connecticut and a Masters degree in Systems Engineering from Gannon University in Pennsylvania.

About Fluidnet

Fluidnet is a developer of advanced IV infusion system solutions that address the growing workflow, connectivity, safety, and regulatory demands across most clinical areas of care. The company currently is finishing the product development, validation, and verification effort, and preparing to submit its 510(k) pre-market notification to the FDA for a multi-use product platform. The system will fully comply with the guidance requirements issued under the agency's new "Infusion Pump Improvement Initiative". For more information see:

SOURCE Fluidnet Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):